首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Prok2 |
| Uniprot No | Q9HC23 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-129aa |
| 氨基酸序列 | MRSLCCAPLLLLLLLPPLLLTPRAGDAAVITGACDKDSQCGGGMCCAVSIWVKSIRICTPMGKLGDSCHPLTRKNNFGNGRQERRKRKRSKRKKEVPFFGRRMHHTCPCLPGLACLRTSFNRFICLAQK |
| 预测分子量 | 14.3kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Prok2(Prokineticin 2)重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：*Expression and Purification of Recombinant Human Prokineticin 2 in Escherichia coli*
**作者**：Cheng, M.Y. et al.
**摘要**：该研究成功构建了人源Prok2的重组表达系统，利用大肠杆菌进行可溶性表达，并通过镍柱亲和层析纯化获得高纯度蛋白。体外实验表明，重组Prok2能够激活其受体PKR1/PKR2.并促进内皮细胞迁移，验证了其生物活性。
2. **文献名称**：*Prokineticin 2 Regulates Circadian Behavior via Signaling through GABAergic Neurons*
**作者**：Li, J.D. et al.
**摘要**：通过注射重组Prok2蛋白至小鼠脑室，研究发现其通过抑制下丘脑GABA能神经元活性，调控生物钟相关基因(如Per1/2)的表达，揭示了Prok2在昼夜节律调控中的关键作用机制。
3. **文献名称**：*Prokineticin 2 Modulates Angiogenesis in Colorectal Cancer via HIF-1α/VEGF Pathway*
**作者**：Ng, K.L. et al.
**摘要**：该研究利用重组Prok2蛋白处理结肠癌细胞，发现其通过上调HIF-1α和VEGF表达促进血管生成，动物实验进一步证实Prok2重组蛋白可增强肿瘤微血管密度，提示其作为癌症治疗潜在靶点。
---
**说明**：以上文献为示例性概括，实际引用需根据具体研究内容检索PubMed或Web of Science等数据库获取完整信息。Prok2重组蛋白的研究多聚焦于神经调控、肿瘤生物学及生殖生理学等领域。
Prokineticin 2 (Prok2) is a small, secreted protein belonging to the prokineticin family, characterized by a conserved N-terminal AVITGA motif and ten cysteine residues forming five disulfide bonds critical for structural stability. It interacts with two G protein-coupled receptors, PKR1 and PKR2. which activate downstream signaling pathways involving calcium mobilization, MAPK, and PI3K/Akt. Prok2 is widely expressed in the central nervous system, gastrointestinal tract, and endocrine tissues, playing diverse roles in physiological processes.
Originally identified for its regulatory effects on gastrointestinal motility, Prok2 is now recognized as a multifunctional cytokine. It modulates circadian rhythms by synchronizing suprachiasmatic nucleus activity, supports neurogenesis and neuronal survival, and promotes angiogenesis through VEGF interaction. Additionally, Prok2 influences pain perception, reproductive functions, and immune responses. Dysregulation of Prok2 signaling is linked to pathologies such as Alzheimer’s disease (via amyloid-beta metabolism), obesity (energy homeostasis disruption), and cancer (tumor angiogenesis and metastasis).
Recombinant Prok2 protein, typically produced in *E. coli* or mammalian expression systems, retains bioactivity for experimental and therapeutic applications. Its production enables studies on receptor binding, signal transduction, and disease mechanisms. Researchers utilize recombinant Prok2 to explore potential therapeutic strategies, including receptor antagonists for cancer or agonists for neuroprotection. Despite progress, challenges remain in understanding tissue-specific signaling nuances and optimizing clinical translation. Current research focuses on elucidating its role in metabolic disorders and neurodegenerative diseases, highlighting Prok2’s significance as a therapeutic target.
×
